Behavioral Neuroscience 2012-12-01

Physical exercise and catecholamine reuptake inhibitors affect orienting behavior and social interaction in a rat model of attention-deficit/hyperactivity disorder.

Andrea M Robinson, Rachel L Eggleston, David J Bucci

Index: Behav. Neurosci. 126(6) , 762-71, (2012)

Full Text: HTML

Abstract

The effects of methylphenidate (MPH), atomoxetine (ATMX), and/or physical exercise (EX) on orienting behavior and social interaction were examined in spontaneously hypertensive rats (SHRs), a commonly used animal model of attention-deficit/hyperactivity disorder (ADHD). During the orienting procedure, rats received repeated presentations of a nonreinforced visual stimulus. As observed previously, orienting behavior (rearing up on the hind legs) habituated across trials in normo-active control rats (Wistars) but not in SHRs, suggesting that SHRs have difficulty ignoring irrelevant behavioral stimuli. Treatment with MPH (0.125 mg/kg), ATMX (0.125 mg/kg), or EX (3 weeks of access to a running wheel), alone or in combination, reduced rearing behavior in SHRs to the level observed in the Wistar control group. Similarly, drug treatment and/or EX reduced the number of social interactions exhibited by SHRs, while having no effects on locomotor activity. It is important to note that EX was just as effective as MPH or ATMX in reducing orienting behavior and social interaction. In contrast to the SHRs, neither MPH nor ATMX affected orienting or social behavior in Wistar rats. Together, these findings support the growing literature that EX may be useful as an adjunctive or replacement therapy in ADHD.


Related Compounds

Related Articles:

Methylphenidate and atomoxetine inhibit social play behavior through prefrontal and subcortical limbic mechanisms in rats.

2015-01-07

[J. Neurosci. 35(1) , 161-9, (2015)]

Atomoxetine prevents dexamethasone-induced skeletal muscle atrophy in mice.

2014-12-01

[J. Pharmacol. Exp. Ther. 351(3) , 663-73, (2014)]

Current pharmacotherapy of attention deficit hyperactivity disorder.

2013-10-01

[Drugs Today (Barc) 49(10) , 647-65, (2013)]

[ADHD register: post-marketing evaluation of the benefit-risk profile of drugs and promotion of the appropriateness].

2013-06-01

[Recenti Prog. Med. 104(6) , 254-61, (2013)]

[Life-threatening heart failure caused by ADHD medication. Five case reports described].

2012-12-01

[Lakartidningen. 109(45) , 2016-8, (2012)]

More Articles...